Allergy Therapeutics Launches Pediatric Trial for Allergy Vaccine
Company Announcements

Allergy Therapeutics Launches Pediatric Trial for Allergy Vaccine

Allergy Therapeutics (GB:AGY) has released an update.

Allergy Therapeutics has begun a groundbreaking Phase III trial for its Grass MATA MPL immunotherapy in children, aiming to tackle grass pollen allergies with a short-course treatment. This follows successful trials in adults, where the therapy showed significant improvement over placebo. Results from this long-term study are anticipated by late 2025, potentially offering a transformative solution for pediatric allergy sufferers.

For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskAllergy Therapeutics Sees Growth and Strategic Advances
TipRanks UK Auto-Generated NewsdeskAllergy Therapeutics Shows Financial Turnaround and Clinical Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App